Lindsey D. Mayo, Ph. D

Lindsey D. Mayo, Ph. D

Associate Professor of Pediatrics

Phone: 317-278-3173
Email: ldmayo@iu.edu
R4 039, 1044 West Walnut St
Indianapolis, IN 46202


Areas of Interest

Understanding how tumor suppressor and oncogenes become altered to promote tumor metastasize and become resistant to conventional therapy.


1992 BS, Life Sciences, Indiana State University
1997 Ph.D, Biomedical Sciences, Wright State University
2003 Post Doctoral Fellow, Department of Microbiology and Immunology Walther Oncology Center, Indiana University School of Medicine

Honors & Awards

  • Sigma Xi Grant-in Aid of Research Award, Calvin S. Fuller Fund 1994
  • Outstanding Poster Award, Wright State University Molecular Biology Retreat 1996
  • Regulation of Hematopoietic Cell Production, NIH T32 1998-2000
  • AACR-AFLAC Scholar-in-Training Award, AACR 2002
  • AACR-Aventis Oncology- Scholar-in-Training Award, AACR 2003
  • Bowman Award first prize for excellence in Post-doctoral research, IUSOM 2003
  • General Motors Cancer Research Scholar Award, General Motors Cancer Research Foundation 2004-2006
  • Invited submission: Department of Defense Era of Hope Breast Cancer Scholar Award 2005
  • Invited submission: Sandler Program for Asthma Research Sandler Asthma Foundation 2006
  • Advisory board for McKenzie Center for Innovation and Technology 2010- present
  • Advisory Board for the College of Arts and Sciences Indiana State University 2012- present
  • Indiana University Trustee’s Teaching award 2013
  • DOD Breast Cancer. Pathology #1 Study Section Reviewer 2004-2006
  • DOD Prostate Cancer, Molecular Biology and Genetics Study Section Reviewer 2005
  • DOD Breast Cancer Research Program, Concept-Molecular Biology and Genetics Reviewer 2006
  • DOD Prostate Cancer, Synergistic Idea Development Award Study Section Reviewer 2007
  • DOD Prostate and Breast Cancer Special Panel Designated New BC PC Reviewer 2007
  • DOD Breast Cancer Review Panel New Reviewer 2008
  • DOD Prostate Cancer Review Panel New Reviewer 2008
  • DOD Impact (2-4) Breast Cancer Reviewer 2008
  • Pennsylvania Department of Health Reviewer 2008
  • DOD Breast Cancer Concept Awards Reviewer 2008
  • Pennsylvania Department of Health Reviewer 2009
  • DOD Breast Cancer Concept PBY-2 Reviewer 2009
  • DOD Breast Cancer Concept PBY-1 Reviewer 2009
  • NIH/ARRA Reviewer 2009
  • DOD Prostate Cancer Concept CMB Reviewer 2010
  • Pennsylvania Department of Health Reviewer 2010
  • DOD Breast Cancer MBG-A Study Section Chair 2011
  • DOD Breast Cancer TRN CBY-1 Study Section Reviewer 2011
  • DOD PRCRP PBT-GCR Study Section Reviewer 2012
  • DOD PCRP CET-1 Reviewer 2013
  • DOD BCRP CET-1 Chair 2013
  • NIH MONC Adhoc Reviewer Jan 2014
  • NIH MONC Adhoc Reviewer Mar 2014
  • NIH/NCI ZRG1F09A-L Adhoc Reviewer Apr 2014
  • NIH/NCI ZCA1 SRLB-5 (M2) B Adhoc Reviewer Apr 2014
  • Veterans Health Administration-Oncology Merit Review Adhoc Reviewer Jun 2014


Research & Grants

RO1 1R01CA172256-01A1 (Mayo) 7/12/13-7/13/18
NIH $250,000 5 calendar months
Regulation of Mdm2 activity by kinase signaling pathways
Goals: Determine the role of kinase signaling pathways in regulating Mdm2 activity to promote tumorigenesis.
Role: PI

R01 (Kacena) 0.6 calendar months
NIH $250,000
Regulation of Osteoblast Function by Megakaryocytes: Key Signaling Proteins Goals: Determine if PYK2 is able to regulate tumor suppressor activity independent of kinase activity. This pathway may activate Mdm2 to stimulate cell cycle progression.
Role: Co-Investigator

R01 CA138798-01A2 (Pollok) 07/15/10-05/31/15 1.20 calendar months
NIH $209,005
Dual Targeting of DNA Repair and p53 pathways for treatment of brain cancer Goals: evaluate in vivo therapeutic efficacy of HDM2 inhibition in combination with temozolomide/irradiation as new treatment for glioblastoma. Aim 1: Develop therapeutic regimens and validate intracellular target modulation mediated by inhibition of HDM2-protein interactions during exposure to DNA-damaging agents. Aim 2: Assess outcome of modulating HDM2-dependent signaling to increase efficacy of TMZ- and/or radiation-mediated DNA damage in ectopic GBM xenograft models. Aim 3: Employ intracranial GBM xenograft models in combination with serial real-time bioluminescence imaging to monitor therapeutic impact of modulating HDM2-dependent signaling in combination with TMZ- and/or radiation-mediated DNA damage.
Role: Co-Investigator



Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. Kinase regulation in inflammatory response. Nature 2000; 406:367-368.

Mayo LD, Donner DB. A PI-3 Kinase/Akt pathway promotes cytoplasmic to nuclear shuttling of Mdm2. Proc. Natl. Acad. Sci. USA. 2001; 98(20) 11598-11603. (Commentary Proc. Natl. Acad. Sci. USA 2001 98(20):10983)

LaRusch GA., Rivera Guzman JR, Dunbar JD, Donner DB, Mayo LD*., VEGF induction is blocked by the Nutlin3 compound by disrupting the interaction between HIF1a and Hdm2. Cancer Research 2007;67(2):450-454

Eitel JA, Bijangi-Vishehsaraei K, Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE, Mayo LD*PTEN and p53 are required to induce expression of the tumor suppressor maspin. Cell Cycle. 2009; 8:(6):1-6. (Commentary Cell Cycle 2009 8(8):1112-3) PMID: 19221500

Araki S, Eitel JA †, Bijangi-Vishehsaraei K. Danielpour D, Pollok KE, Boothman DA, Mayo LD*. TGF?1 induced expression of Mdm2 correlates with late stage metastatic breast cancer. Journal of Clinical Investigation. 2010 Jan 4;120(1):290-302. PMCID: PMC2798681

Waning DL†, Lehman JA†, Batuello CN†, Mayo LD*. c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation. J Biol Chem. 2011 Jan 7;286(1):216-22. PMCID: PMC3012977

Lehman, JA†, Waning DL†, Batuello CN†, Cipriano R†, Kadakia MP, Mayo LD*. Induction of Apoptotic Genes by a p73-Phosphatase and Tensin Homolog (p73-PTEN) Protein Complex in Response to Genotoxic Stress. J Biol Chem. 2011 Oct 21;286(42):36631-40 PMCID: PMC3196149

Cheng YH, Hooker RA, Nguyen K, Gerard-O'Riley R, Waning DL, Chitteti BR, Meijome TE, Chua HL, Plett AP, Orschell CM, Srour EF, Mayo LD, Pavalko FM, Bruzzaniti A, Kacena MA. Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation. J Bone Miner Res. 2013 Jan 29. doi: 10.1002/jbmr.1876

Wang H, Cai S, Ernstberger A, Bailey BJ, Wang MZ, Cai W, Goebel WS, Czader MB, Crean C, Suvannasankha A, Shokolenkoc I, Wilson GL, Baluyut AR, Mayo LD, Pollok KE. Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways. Clin Cancer Res. 2013 May 15;19(10):2699-709. doi: 10.1158/1078-0432.CCR-12-2671.

Lehman JA, Hauck PM, Gendron JM, Batuello CN, Eitel JA, Albig A, Kadakia MP, and Mayo LD. Serdemetan Antagonizes the Mdm2-HIF1? Axis Leading to Decreased Levels of Glycolytic Enzymes. PLoS One. 2013 Sep 6;8(9): e74741. doi:10.1371/journal.pone.0074741.